Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beate Wieseler

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Health Policy (Amsterdam, Netherlands)|January 30, 2014
Early benefit assessment of new drugs in Germany - results from 2011 to 2012Helmut Hörn, Katrin Nink, Natalie McGauran, et al.
Systematic Reviews|November 1, 2012
Access to regulatory data from the European Medicines Agency: the times they are a-changingBeate Wieseler, Natalie McGauran, Michaela F Kerekes, et al.
BMJ (Clinical Research Ed.)|April 3, 2023
Authors' reply to Morales and ArlettBeate Wieseler, Mattias Neyt, Thomas Kaiser, et al.
BMJ (Clinical Research Ed.)|March 2, 2023
Replacing RCTs with real world data for regulatory decision making: a self-fulfilling prophecy?Beate Wieseler, Mattias Neyt, Thomas Kaiser, et al.
Plos One|August 11, 2016
Assumptions of Mixed Treatment Comparisons in Health Technology Assessments - Challenges and Possible Steps for Practical ApplicationStefanie Reken, Sibylle Sturtz, Corinna Kiefer, et al.
BMJ (Clinical Research Ed.)|January 5, 2012
Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publicationsBeate Wieseler, Michaela F Kerekes, Volker Vervoelgyi, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 20, 2014
[Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences]Tatjana Kvitkina, Anette ten Haaf, Stefanie Reken, et al.
BMC Rheumatology|December 9, 2022
A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritisKirsten Janke, Corinna Kiefer, Natalie McGauran, et al.
International Journal of Technology Assessment in Health Care|March 10, 2015
Endpoints for relative effectiveness assessment (REA) of pharmaceuticalsMira Pavlovic, Conor Teljeur, Beate Wieseler, et al.
Trials|April 15, 2010
Reporting bias in medical research - a narrative reviewNatalie McGauran, Beate Wieseler, Julia Kreis, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Health Policy (Amsterdam, Netherlands)|January 30, 2014
Early benefit assessment of new drugs in Germany - results from 2011 to 2012Helmut Hörn, Katrin Nink, Natalie McGauran, et al.
Systematic Reviews|November 1, 2012
Access to regulatory data from the European Medicines Agency: the times they are a-changingBeate Wieseler, Natalie McGauran, Michaela F Kerekes, et al.
BMJ (Clinical Research Ed.)|April 3, 2023
Authors' reply to Morales and ArlettBeate Wieseler, Mattias Neyt, Thomas Kaiser, et al.
BMJ (Clinical Research Ed.)|March 2, 2023
Replacing RCTs with real world data for regulatory decision making: a self-fulfilling prophecy?Beate Wieseler, Mattias Neyt, Thomas Kaiser, et al.
Plos One|August 11, 2016
Assumptions of Mixed Treatment Comparisons in Health Technology Assessments - Challenges and Possible Steps for Practical ApplicationStefanie Reken, Sibylle Sturtz, Corinna Kiefer, et al.
BMJ (Clinical Research Ed.)|January 5, 2012
Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publicationsBeate Wieseler, Michaela F Kerekes, Volker Vervoelgyi, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 20, 2014
[Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences]Tatjana Kvitkina, Anette ten Haaf, Stefanie Reken, et al.
BMC Rheumatology|December 9, 2022
A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritisKirsten Janke, Corinna Kiefer, Natalie McGauran, et al.
International Journal of Technology Assessment in Health Care|March 10, 2015
Endpoints for relative effectiveness assessment (REA) of pharmaceuticalsMira Pavlovic, Conor Teljeur, Beate Wieseler, et al.
Trials|April 15, 2010
Reporting bias in medical research - a narrative reviewNatalie McGauran, Beate Wieseler, Julia Kreis, et al.
Pageof 5